Drug · DIN 02459175
QTERN
No: cancelled before it was sold
Authorized, then cancelled before it was ever sold in Canada.
Status Cancelled Pre Market since September 26, 2022.
- Drug Identification Number (DIN)
- 02459175
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Saxagliptin and dapagliflozin A10BD21
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) | 5 MG | |
| DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) | 5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 22, 2016: NOC 18684New Drug Submission (NDS)
Other DINs named QTERN
- DIN 02459183 · Cancelled Pre Market